

Gynecology Oncology (GynOnc) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

**PLATINUM-RESISTANT****GOG-3076**

Platinum Doublet + Bevacizumab +/-OlviVec
>3L

PI: Tewari

CRC: Jiana Ejbara

Accrual: 3/5

ETCTN 10422

Abemaciclib + Olaparib

PI: Dwabe

CRC: Jiana Ejbara

Accrual: 0/5

NEWLY DIAGNOSED**GOG-3135**

GSK5733584 +/- Bevacizumab
HR proficient

PI: Tewari

CRC: Jiana Ejbara

Accrual: 0/5

PLATINUM-SENSITIVE**GOG-3136**

GSK5733584 + Bevacizumab Vs. Platinum
doublet + Bevacizumab

PI: Tewari

CRC: Jiana Ejbara

Accrual: 0/5



GOG-3123

Sacituzumab Tirumotecan + Pembrolizumab +/-
Bevacizumab VS. SOC

1L Maintenance

PI: Tewari

CRC: Jiana Ejbara

Accrual: 0/5

NRG-GY037

Chemoradiation with pembro, followed by
pembro maintenance +/- induction therapy of
chemo & pembro

No prior treatment

PI: Healy

CRC: Jiana Ejbara

Accrual: 2/5



GOG 3119

Pembro +/- Sacituzumab Tirumotecan
For pMMR
1L or 1 prior
PI: Tseng
CRC: Jiana Ejbara

Accrual: 2/5

NRG-GY026

Carbo/Taxol +/- Trastuzumab/hyaluronidase or
pertuzumab/trastuzumab/hyaluronidase
For HER2 +
No prior treatment
PI: Tewari
CRC: Jiana Ejbara

Accrual: 0/5

GOG 3110

AZD8205 (ADC) vs. Physicians Choice for B7-H4
positive endo
≤ 2 prior lines
PI: Tseng
CRC: Jiana Ejbara

Accrual: 0/5



UCI 24-146

REGN5668 + REGN4018 or Cemiplimab
Endometrial or ovarian (SLOT RSVP REQ)

PI: Tseng

CRC: Jiana Ejbara

Accrual: 2/5

UCI 24-142

VET3-TGI +/- Atezolizumab

PI: Uchio

CRC: Jiana Ejbara

Accrual: 1/5

UCI 24-08

SPEDOX-6 for 2L+ cervical, uterine or ovarian
SLOT RSVP REQ

PI: Chow

CRC: Jiana Ejbara

Accrual: 7/25

UCI 24-176

Raludotatug Deruxtecan
Endometrial, Ovarian, & Cervical
SLOT RSVP REQ

PI: Mar

CRC: Jiana Ejbara

Accrual: 0/5



UCI 24-05

Riluzole PO vs. Placebo PO
Perceived worsening of cognitive function
CRC: Jiana Ejbara
Accrual: 24/39